Market Cap | 3.90M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -1.64M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 2.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -47.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -66.00% |
Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 407.07M | 52W Low Chg | 3.00% |
Insider Own | 1.67% | ROA | -389.60% | Shares Float | 379.03M | Beta | 0.48 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.01 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 166,446 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 18 | Volume | 68,400 | Change | 1.95% |
GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. is based in Las Vegas, Nevada.